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Objective: A disposable autoinjector was developed for subcutaneous (SC) self-injection by 
patients with chronic diseases. To verify its performance and evaluate its acceptance, a clinical 
study was conducted in healthy volunteers, comparing SC injections performed by subjects 
using the autoinjector with SC injections performed by nurses using a syringe.
Methods: This was a randomized, single-center, crossover study comparing SC self-injection 
using an autoinjector with SC nurse-administered injection using a syringe. Two volumes (0.2 mL 
and 1 mL) were injected into healthy volunteers. Study objectives included assessment of the 
accuracy and consistency of the volume injected by the injection systems, and skin reaction and 
pain associated with the injection. The fluid depot in the SC tissue layer was evaluated by 
ultrasound. Subject acceptance was evaluated using questionnaires on attitudes and emotions 
towards the injection technique, and challenged by seeking the subjects’ preferred system for 
a final study injection or future treatment.
Results: A total of 960 injections (480 with autoinjector, 480 with syringe) were performed in 
40 subjects. There were no significant differences in mean fluid leakage and injected volumes 
between the systems. Pain associated with the injection was significantly lower with the auto-
injector than with the syringe. Local skin reaction at the injection site was overall satisfactory. 
Injections were appropriately performed by all subjects. At study end, all 40 subjects preferred 
the autoinjector for a final study injection and for future treatment.
Conclusion: This study indicated that the autoinjector used by the subject was similar to a 
syringe used by a nurse in terms of performance and safety in administering the injections, and 
better in terms of pain, overall acceptance, and preference.
Keywords: subcutaneous injection, autoinjector, self-injection, injection pain, preference, 
acceptance
Introduction
Chronic autoimmune inflammatory diseases, such as rheumatoid arthritis (RA), multiple 
sclerosis (MS), and Crohn’s disease, are progressive conditions associated with disability, 
morbidity, and mortality.1 The introduction of injectable disease-modifying drugs a decade 
ago has had a considerable impact on the progression of such diseases, arresting joint 
deformities in RA and disease exacerbation in MS for extended   periods.2 Consequently, 
patients’ adherence to treatment has become a major requisite for achieving optimal 
treatment efficacy and expected therapeutic outcome.3 Factors that influence compliance 
with injectable treatment in RA remain underinvestigated, while more of these newer Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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injectable biologics are   becoming available for use.4 recent 
report has suggested that for chronic injectable treatment, self-
injection is associated with better compliance than injection by 
a family member or by a health care professional.4
A self-administered injectable drug should provide 
patients with a better quality of life due to the increased 
autonomy and flexibility in adhering to the treatment regimen. 
Ready-to-use, disposable autoinjectors, prefilled with a fixed 
drug dose, are currently under clinical development.
This article reports the results of a clinical trial evaluating 
the performance, safety, and subject acceptability of a newly 
developed, disposable autoinjector for subcutaneous (SC) 
injection, which has been specifically designed to improve 
adherence to an injection schedule. The primary study objec-
tive was to evaluate the performance of the prefilled autoin-
jector used by the subjects relative to standard SC injection 
by nurses using a prefilled syringe. Secondary objectives 
were to assess the subjects’ pain during the injection, skin 
reaction, and their compliance with the instructions for use 
(IFU). Finally, subject preference for self-injection or for 
injection by a nurse was investigated.
Material and methods
study design
This study was a randomized, single-center, crossover study 
comparing self-injection with injection by nurses in healthy 
volunteers. The study was conducted in France after approval by 
the Ethics Committee, and in compliance with the   latest revision 
of the Declaration of Helsinki, and with Good Clinical Practice 
according to European directives and French laws. Each subject 
came for three separate sessions of eight injections. The order 
of injections was balanced across all subjects in terms of the 
system, volume, and injection site, and subjects were randomly 
assigned to a prespecified order of injection (see Figure 1). An 
independent observer watched each injection and reported 
noncompliance with the injection procedure according to a pre-
established list of items, including subject errors when handling 
the autoinjector and performing the injection.
subjects
Subject selection and recruitment, and the clinical phase of the 
study were conducted by a French investigation center (Eurofins 
Optimed, Grenoble, France). The required number of subjects 
was 40. The main eligibility criteria were the following: healthy 
men and women aged 25–35 years or 45–65 years, free of 
drugs having an impact on pain perception during the clinical 
investigations (last drug intake at least six elimination half-lives 
before injection), without previous experience of self-injection 
or giving injections, and without current visible skin disease 
at the targeted injection sites. The group aged 25–35 years 
was selected to correspond with the age of onset of MS, while 
subjects in the group aged 45–65 years represented those in 
the RA population. Subject selection was based on reported 
clinical history, physical examination, blood tests, absence of   
ongoing chronic disease, and concomitant treatment.
injection system and injection procedures
The standard injection system used by the nurses was a 1 mL 
sterile, single-use, prefilled glass syringe (BD Hypak™; 
BD, Franklin Lakes, NJ), and the investigational system 
was the newly developed, prefilled, ready-to-use, single-
use autoinjector used by the subject for self-injection (BD 
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Physioject™). The prefilled BD Hypak syringe and the 
prefilled syringe assembled inside the autoinjector were 
the same, with a preattached needle (27 gauge, 12.7 mm). 
Syringes were prefilled with sterile, pyrogen-free, saline 
(0.9% sodium chloride) solution. The two injection volumes 
evaluated (0.2 mL and 1 mL) correspond to the minimum 
and maximum volumes targeted to be injected with the BD 
Physioject disposable autoinjector. Prior to the study, all 
subjects were individually trained to perform SC injections 
into a skin-fold using the autoinjector. The IFU comprised 
10 steps. To counteract any variability between health care 
professionals on the subjects’ cognitive perception of the 
injection, 14 nurses performed the injections with prefilled 
syringes, and each subject had a different nurse at each of 
the three sessions. Nurses performed SC injections accord-
ing to their usual technique with a skin-fold.
Assessments
The accuracy and consistency of the injected volume was 
  evaluated by gravimetric methodology using a 0.01 mg pre-
cision balance (Sartorius BD211D™ E2 precision class).5 
The injection system weight was recorded before and after 
each   injection, and the fluid leakage volume was assessed 
by   collecting the fluid on the skin surface at the injection site 
immediately after completion of the injection, using ophthalmic 
sponges. The injected volume was calculated based on the 
weight of the injection systems before and after injection, and 
the weight of the sponges before and after leakage collection.
Fluid injection into the hypodermis changes the local 
ultrasound echostructure of the tissue. Therefore, the injected 
fluid depot in the hypodermis layer was determined immedi-
ately after injection completion using ultrasound sonography 
(Logiq 500™, 11 MHz two-dimensional probe, in mode B; 
GE Medical Systems, Chalfont St Giles, UK). The fluid depot 
location in the body tissue layers was determined by measur-
ing the distance (in mm) between the skin surface and the 
bottom of the fluid depot. This noninvasive method increased 
the duration of the subjects’ sessions in the clinical center. 
Because this was an exploratory objective, it was considered 
sufficient to perform ultrasound assessment on a full set of 
eight injections from one session only, for all subjects.
Subjects’ pain during the injection was measured using a 
100 mm visual analog scale (VAS) ranging from “no pain” to 
“very painful”, and a verbal scale with a choice of eight answers 
ranging from “I did not perceive anything” to “I perceived an 
intense pain”.6,7 double measurement in millimeters (VAS and 
verbal scale) was performed by two clinical trial technicians. 
Subjects completed one VAS and one verbal scale immediately 
after each injection. Local skin reaction was scored after visual 
inspection of the injection site, recording redness (erythema), 
bleeding, bruising, edema, and itching. These criteria were used 
to determine each subject’s acceptance of the treatment.7
The overall subject preference regarding self-injection 
compared with injection by a nurse was evaluated using 
specifically designed questionnaires assessing a subject’s 
emotions and attitudes.8–10 Evaluations were made before 
initiating the investigation and after each session. At the 
end of the last injection session, subjects were asked to 
choose between self-injection and injections by nurses for 
an additional unscheduled injection. In addition, they were 
asked which combination of systems they would prefer 
should they ever need a chronic treatment administered by 
SC injection, ie, a nurse giving the injection using a syringe 
or an autoinjector, or performing self-injection themselves 
using a syringe or an autoinjector.
Data analysis
Data were analyzed using the SAS® computer program 
(version 8.2; SAS Institute, Cary, NC). With regard to the 
primary objective, a 95% confidence limit for the 95th per-
centile of the “fluid leakage” population was calculated per 
system and per injection volume. The 95% upper confidence 
limit was compared with 10 µL for the 0.2 mL injection 
volume, and with 50 µL for the 1 mL injection volume. A 
repeated-measures mixed model with subjects as random 
effects, device, gender,   session, and site as fixed effects, 
and age as a covariable was used to compare performance 
(average fluid leakage volume and injected volume), average 
pain, and average fluid depot depth between the two systems 
per body site and per injection volume. In the presence of 
non normality, analysis was performed after a normalizing 
transformation of the data. Skin reactions were analyzed 
using ordinal logistic regression (edema and bleeding), or 
Fisher’s exact test when the number of positive observa-
tions was small (itching, bruising, and erythema). Data on 
compliance with self-injection IFU were analyzed using a 
mixed model, whereas data on preference, emotions, and 
attitudes were analyzed using comparative t-tests and, where 
relevant, analysis of variance.
Skin reactivity and acceptance were analyzed on the safety 
set corresponding to all injections of all subjects randomized 
who had at least one injection, including subjects prematurely 
withdrawn. The per protocol (PP) set   corresponded to the 
safety set with no major protocol   deviation. Injection system 
performance (except for ultrasound assessment) and subject 
pain were analyzed on the PP set, taking into account all Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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injections (24 per subject, 40 subjects, ie, 960 injections). 
Ultrasound assessment was analyzed on the restricted subset 
of eight injections per subject in the PP set (ie, 320 injec-
tions). Compliance with self-injection IFU was analyzed 
on the PP set, taking into account all self-injections (ie, 
480 injections with the autoinjector). Subject preference was 
analyzed on the PP set, taking into account the opinion of 
each subject (ie, 40 subjects’ answers).
Results
Analysis of population
Of the 62 subjects screened, a total of 40 healthy volunteers 
were enrolled, as described in Table 1. All 960 planned injec-
tions were performed and analyzed. Due to the absence of 
premature withdrawal, the safety set and PP populations were 
the same, and had an effective of 960 injections (480 with 
syringes, 480 with autoinjectors).
injection system performance
The data summary results on fluid leakage and injected 
volume are reported in Table 2. Fluid leakage was not col-
lected for 88 injections, mostly because of blood droplets 
at the injection site. The mixed-model analysis indicated no 
significant effect of testing factors on leakage volume and 
injected volume. The only exception to this was gender, but 
this effect was not clinically significant, ie, leakage volume 
was higher in female (2.7 µL) than in male subjects (1.6 µL, 
P = 0.0003), and injected volume was higher in male (0.207 
and 1.014 mL) than in female subjects (0.206 and 1.011 mL, 
respectively, P = 0.0037). The rate of injected volume below 
the expected injected volume was six of 480 injections with 
the autoinjector (five and one injections for 0.2 mL and 
1 mL, respectively) compared with 17 of 480 with the 
syringes (eight and nine injections for 0.2 mL and 1 mL, 
respectively). Whatever the injected volume, the estimate 
of the 95th   percentile of leakage volume and its 95% con-
fidence interval (CI) were below the threshold of 5% of 
injection volume. These results indicate that the accuracy 
and consistency of the volume injected by self-injection 
are not significantly different from injections given by 
nurses.
In total, 320 ultrasound assessments were performed, 
comprising 160 after injections by a nurse and 160 after self-
  injections. For one injection, delivering a fluid volume of 1 mL 
by autoinjector, no fluid depot was detected on ultrasound exam-
ination. Fluid depot location in the hypodermis after injection 
was detected using ultrasound sonography for 159 injections 
across 160 analyzed injection sites. Figure 2 presents a box plot 
(arithmetic mean, median, and minimum and maximum values) 
of depth of the injection fluid depot from the skin surface. The 
mixed-model analysis indicated no significant difference in 
depth of the fluid depot between the two groups. No effect of 
body site or of injected volume was detected.
subject pain, skin reaction,  
and acceptance
Pain measured by a VAS immediately after each of the 
960 injections is reported in Figure 3 and Table 3. Subjects 
reported significantly less pain when injections were self-
administered by the autoinjector than when given by nurses 
with the syringe (P , 0.0001), and with an injection of 
0.2 mL rather than 1.0 mL (P = 0.0003). Female subjects 
reported less pain than male subjects (P , 0.0001). Similar 
significant differences were also recorded using the verbal 
scale, except for the gender effect. As detailed below regard-
ing subject acceptance, the reduction in pain was associated 
with a preference for self-injection.
Skin reactions at the injection site immediately after 
each of the 960 injections are reported in Table 4. The most 
frequent local reaction was bleeding, seen mostly as a spot of 
blood corresponding to needle penetration through the skin. 
This very minor local bleeding was recorded more frequently 
with self-injections than with syringes (43.1% versus 10.6%, 
respectively). Local edema was observed in a few cases and 
was more frequent with injections by nurses.
A total of 15 adverse events occurred following the 960 injec-
tions (15/960, 1.6%), all of which were of mild intensity and 
resolved spontaneously by the end of the study. The only sys-
temic adverse event was vague malaise after manual injection 
by a nurse. Most adverse events comprised delayed hematoma 
in 14/960 cases (1.4%) at the injection site. The autoinjector 
was responsible for six cases of delayed hematoma and the 
syringe was responsible for two cases; identification of the 
causative injection system was not possible in six of 14 
cases due to the delay in onset.
Table 1 screening and inclusion population
Screened 
subjects
Included 
subjects
Age strata
25–35 years 45–65 years
n = 62 n = 40 12 male 8 male
8 female 12 female
Mean age (sD) Mean age (sD)
28.8 (2.8) years 54.5 (5.8) years
Notes: nonincluded subjects, n = 22. eight subjects removed their consent, seven 
subjects didn’t satisfy eligibility criteria, and seven subjects were not included because 
age strata was already full when the center obtained all their screening results.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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compliance with self-injection 
instructions for use
Based on the observation by a nurse of the 480 injections 
performed by the subjects with the autoinjector, the mean 
percentage of steps performed in compliance with IFU was 
92.9% (95% CI: 92.3%–93.6%). An age effect was detected, 
with greater compliance among younger subjects (93.6% 
in the group aged 25–35 years versus 92.0% in the group 
aged 45–65 years, P = 0.0163), but this is not clinically   
relevant.
subject preference for self-injection, 
emotions, and attitudes
The 40 subjects completed a questionnaire about their emo-
tions, attitudes, and preference. Subjects’ emotions regarding 
self-injection were reflected in words such as “pleasant”, 
Table 2 Fluid leakage and injected volume, gravimetric method (primary endpoint) – per protocol populationa
Volume System N Leakage (μL) Injected volume (μL)
Mean 
(SD)
Median 
(MAD)e
Mean 
(SD)
Median 
(MAD)e
0.2 ml self-injection/subject 205 1.7
(2.4)
1.0
(1.0)
206.8
(8.0)
207
(4)
syringe/nurse 233 2.1
(2.6)
1.0
(1.0)
206.6
(5.8)
208
(2)
1 ml self-injection/subject 206 3.3
(17.5)c
1.0
(1.0)
1013.0
(19.9)
1015
(4)
syringe/nurse 227 1.6
(2.0)
1.0
(1.0)
1012.0
(7.1)
1013
(3)
Total of analyzed injections 871
Missing data 1 missing value for an injection by a nurseb
88 leakages were not collectedd
Total of performed injections 960
Notes: athe per protocol population is the study population used for the main criteria analysis (excluding the 88 cases without leakage collection); bone missing value for 
an injection into the abdomen by a health care professional; cthis mean (SD) is inflated by an outlying value of 223 µL (the mean [sD] without this outlying value is 2.2 µL 
[8.5 µL]); dWhen the leakage was not collected it was impossible to calculate the injected volume. cases without leakage collected (n = 88) were excluded from main criteria 
analysis; eMedian Absolute deviation.
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Figure 3 Perceived pain, 100 mm visual analog scale (VAs; secondary endpoint) – per protocol population.
“comforting”, “reassuring”, and “less anxious” (14/40, 35%). 
Ease of use (10/40, 25%) and the autonomy associated with 
self-injection (8/40, 20%) were also deemed important.
A majority of subjects reported positive attitudes and emo-
tions with self-injection. However, statistical analysis showed 
that injection by a nurse was perceived as “easier”, “reliable”, 
and more “reassuring” compared with   self-injection.
When subjects were asked which injection system they 
would prefer for an additional unforeseen injection, all 
subjects selected self-injection. In the event that they ever 
needed chronic treatment administered by SC injection, 
subjects ranked self-injection with the autoinjector first   
(Figure 4).
Discussion
This study is the first clinical trial in humans evaluat-
ing the newly developed autoinjector BD Physioject. 
Because the main objectives were to document the intrinsic 
  performance, safety, and subject acceptance of the injection 
system, the trial was conducted in healthy volunteers using 
a placebo solution. The demographic characteristics of the 
enrolled subjects were well matched to those reported for 
MS and RA populations.11,12
Ultrasound is an accurate method of measuring depth 
of the fluid depot in SC tissue. It has been used in previous 
studies at similar injection sites, and in subjects of similar age 
and gender to those participating in this study. We used a two-
dimensional ultrasound method with an 11 MHz probe. The 
reliability of this imaging technology was confirmed by two 
previous studies using two-dimensional ultrasound assess-
ment to detect, respectively, 0.1 mL and 0.5 mL injections 
of saline solution in SC tissue, with a 5 MHz and a 16 MHz 
probe, respectively.13,14
Performance and variability in injected volume accu-
racy with self-injections were not significantly different 
from those associated with injections given by nurses. 
Indeed, regardless of the system, fluid leakages were in 
the range of a few microliters for a total injected volume 
of 0.2 mL or 1 mL. Of note, the volume per injection of 
most of the drugs approved or in clinical development 
for autoimmune inflammatory diseases is at least 0.5 mL. 
In the present study, the rate of injected volume below 
the expected injected volume was six of 480 injections 
with the autoinjector compared with 17 of 480 with the 
syringes.
The injected fluid depot in the hypodermis was observed 
in 98.8% of SC self-injections and 100% of injections 
  administered by nurses. Subjects were asked to make a skin-
fold, which was not obvious to healthy subjects who are naïve 
to injection practice, and resulted in skin-folds that were 
highly variable in size and quality. Skin-folds made by nurses 
were more alike. One injection fluid depot by self-injection 
was detected at a depth of 6.6 mm from the skin surface, most 
likely because the subject had a very low body mass index 
(18.3 kg/m²). Another injection fluid depot was at a depth of 
3.3 mm, and categorized as located in the shallow hypoder-
mis. Studies evaluating SC skin thickness using ultrasound 
evaluation have reported a mean abdomen SC skin thickness 
ranging from 12.2 mm to 40.2 mm according to gender and 
body mass index,14,15 and a mean anterior thigh SC skin 
thickness ranging from 7.6 mm to 14.3 mm.14,16 Therefore, a 
12.7 mm depth of needle insertion with a skin-fold procedure Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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should ensure that the injection of fluid is made into the SC 
tissue layer, regardless of the subject’s body characteristics 
(including body mass index).
Subject pain with the self-injection system was lower 
than the values usually reported in studies using a 100 mm 
VAS, while pain following injection by a nurse was within 
the previously reported range.7 Because pain is recognized 
as a factor impacting on subject compliance and injection 
anxiety, many clinical evaluations have investigated possible 
factors impacting on perceived pain. Needle sharpness and 
smaller needle diameter contribute significantly to reducing 
injection pain.7 The autoinjector’s automatic needle   insertion 
into the skin might therefore contribute to minimizing per-
ceived pain.17 Considering the published data and the pain 
scores reported in the present study, pain was minimized by 
use of the autoinjector, which combines a prefilled syringe 
with a 12.7 mm, 27-gauge staked needle and automated 
needle insertion (8 mm exposed). Minimal pain was also 
reflected in the results of the verbal scale, which ranged 
from “hardly perceptible, without pain” to “perceptible, 
slightly painful”.
Among other factors, slow speed of injection18 and 
the injectable drug formulation (especially fluids that are 
particularly acidic or basic)19 are reported as significantly 
influencing perceived pain. In a recent study in 40 healthy 
volunteers, pain associated with SC injection of a 0.9% 
saline solution was scored 14 ± 20 mm on a 100 mm VAS.20 
Half of the subjects experienced no pain on injection 
according to a six-item verbal scale. In another study in 
84 healthy volunteers, the pain associated with SC injec-
tion of a saline solution was of similar magnitude (mean 
pain at injection 16.0 mm, 95% CI: 12.4%–19.7%).21 An 
improvement in drug formulation may also contribute to 
minimizing perceived pain, and this has been demonstrated 
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Table 4 Local skin reactions at injection site – safety populationa
Auto-injector/ 
subject
Syringe/ 
nurse
Bleedingb
n (%)
207 (43.1) 51 (10.6) P , 0.0001c
edema
n (%)
16 (3.3) 92 (19.2) P , 0.0001c
Bruising
n (%)
3 (0.6) 1 (0.2) not
significantd
itching
n (%)
1 (0.2) 0 (0.0) not
significantd
erythema
n (%)
6 (1.3) 5 (1.1) not
significantd
Notes:  athe  safety  population  includes  all  subjects  with  at  least  one  injection; 
b132/207 (63.8%) for Auto-injector/subject and 30/51 (58.8%) for syringe/nurse are 
categorized as “just a spot”; cfrom ordinal logistic regression; dFisher’s exact test.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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with the improved formulation of interferon beta 1b (Rebif®; 
Merck Serono SA, Geneva, Switzerland). It would therefore 
be of interest to evaluate pain at the injection site using 
the autoinjector in combination with the drug and in target 
patient populations.
Local skin reaction may also have a significant impact on 
patient compliance with chronic treatment with injectables. 
Local bleeding was more frequent with self-injections than 
with injections administered by nurses. However, in 63.8% 
of injections, bleeding was limited to “just a visible spot” 
at the injection site and, because the subjects did not spon-
taneously complain, it is unlikely that this would affect a 
patient’s long-term acceptance of self-injections. Further 
investigation is warranted in clinical studies with injectable 
drugs, because bleeding might be influenced by the nature 
of the injected solution. All other items contributing to local 
skin reaction were comparable between the autoinjector 
and the syringe.
Hematomas were reported after injection in a few 
cases (15/960, 1.5%). The incidence of hematoma is infre-
quently reported in clinical studies, but the hematoma rate 
in the present study was considered comparable with that 
usually observed after SC injections of drugs other than 
anticoagulants. In a study of injections of placebo or eryth-
ropoietin, two hematomas at the injection site were recorded 
after 120 injections (1.7%).22 In contrast, one study reported 
a 25% rate of hematoma after SC injection of low molecular 
weight heparin using a standard 26-gauge needle.18
Compliance with IFU for the self-injection system was 
evaluated at 93%, which was slightly, but significantly, higher 
among younger than older subjects. Regardless, an overall 
rate of over 90% compliance was considered good, consid-
ering that the subjects were initially naïve at   performing 
self-injections (excluding initial study   training). Subject 
adaptability to using the self-injection system was consid-
ered a good predictor of ease of use. Moreover, the positive 
attitudes of the subjects towards self-injections also reflected 
their acceptance of the autoinjector. Attitudes reflecting fear 
of pain generally lead to poor treatment compliance and 
avoidance behavior, while compliance may be improved by 
confidence building and reassurance.23
All 40 subjects selected self-injection at the end of the 
study, suggesting that the autoinjector is the preferred injec-
tion system. Subjects also selected self-injections using the 
autoinjector when asked which combination of operator and 
system they would prefer for weekly SC injections to control 
9
8
7
6
A
c
c
e
p
t
a
b
i
l
i
t
y
5
4
3
2
1
8.95
7.23
Interval plot of acceptability
95% CI for the mean
2.63
Auto-injector
(Physioject TM )
Auto-injector
(Physioject TM )
Syringe
Syringe
Self-injection Injection given by a nurse
5.98
Figure 4 Device acceptability score for four injection scenarios (mean and 95% confidence interval).
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a chronic disease. The autoinjector handled by a nurse was 
ranked second, indicating that the autoinjector was pre-
ferred over the syringe, regardless of who is performing 
the injection. Preference for the autoinjector is probably a 
result of the system’s features, such as low perceived pain, 
practicability, and ease of use. The results require further 
investigation in patients with chronic diseases and with 
injectable drugs, and relative to other autoinjectors with 
different features.
Conclusion
In terms of technical performance, self-injection with the 
BD Physioject was not significantly different from injections 
using similar but “naked” syringes administered by nurses. 
There was no significant difference in the depth of the injec-
tion fluid depot between the two systems. Neither injection 
volume nor body site effected performance.
Self-injection with the BD Physioject was associated 
with greater acceptance, which was likely related to its self-
injector features, including a low perception of pain, regard-
less of the site of administration (abdomen or thigh). Body 
site, gender, and injection volume did not affect perceived 
pain or acceptance.
A few skin reactivity events (mainly some visible spots 
and drops of blood at the injection site), and a few adverse 
events of mild intensity which spontaneously resolved at 
the end of the study were observed, and demonstrated good 
clinical tolerance and good local skin tolerance of the two 
systems.
The observed errorless handling of the autoinjector when 
giving self-injections, in compliance with the IFU, suggests 
that the system is convenient and easy to use.
In conclusion, this study demonstrated that self-injection 
with the BD Physioject is an efficient, safe, and intuitive 
procedure, very well accepted by subjects and preferred 
to an injection by a nurse. Improved treatment compliance 
may therefore be anticipated in patients with chronic disease 
requiring injectable treatment, based on the subjects’   positive 
attitudes and spontaneously expressed preference for the 
autoinjector.
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